NIH R01 · 2024
Preservation of DCD Allograft Integrity for Liver Transplantation
PROJECT SUMMARY Liver transplantation is the only definitive therapy for end-stage liver disease. A significant pool of liver donors comes from donation after cardiac death (DCD). The challenge with DCD donors is the prolonged warm ischemia that can result in significant liver dysfunction, thus leading to the development of early allograft dysfunction (EAD) or even primary non-function (PNF) in the recipient. Development of a therapeutic agent to preserve DCD liver donor integrity would have significant therapeutic value in reducing EAD/PNP during or after a liver transplant. Previously we identified MG53 as an essential component of cell membrane repair. In this proposal, we present…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.